Regentis Biomaterials (RGNT) Common Equity (2024 - 2025)
Regentis Biomaterials' (RGNT) quarterly Common Equity came in at $4.7 million in Q4 2025, up 111.54% year-on-year from $2.2 million in Q4 2024, and up 111.54% on a QoQ basis from -$41.1 million in Q4 2024.
Regentis Biomaterials (RGNT) Common Equity (2024 - 2025) Analysis & Trends
Regentis Biomaterials (RGNT) has 2 years of Common Equity data on file, last reported at $4.7 million in Q4 2025.
- On a quarterly basis, Common Equity rose 111.54% year-over-year to $4.7 million in Q4 2025; TTM through Dec 2025 was $4.7 million, a 111.54% increase from a year earlier, with the FY2025 full-year figure at $4.7 million, up 111.54% from the prior year.
- Common Equity for Q4 2025 stood at $4.7 million, up from -$41.1 million in the prior quarter.
- Over the last five years, Common Equity for RGNT reached as high as $4.7 million in Q4 2025 and fell as low as -$41.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | 22.13 Bn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | 18.30 Bn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | 24.13 Bn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | 11.27 Bn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | 6.49 Bn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | 2.99 Bn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | 8.24 Bn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | 4.97 Bn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | 4.15 Bn |
| 10 | Regentis Biomaterials | 1.10 Mn | -6.28 Mn | - | 4.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.74 Mn |
| Dec 31, 2024 | -41.10 Mn |